Telomerase reverse transcriptase variant
AssigneeUniversity of Medicine and Dentistry of New Jersey
InventorJanine H. Santos
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic and amino acid sequences of a novel variant of the telomerase reverse transcriptase. More particularly, the present invention is directed to a novel variant of human telomerase reverse transcriptase, which displays properties distinct from those of wildtype telomerase reverse transcriptase, and methods of use thereof.
Claims19
An isolated nucleic acid sequence encoding a polypeptide comprising SEQ ID NO:
- 2, wherein said polypeptide increases sensitivity of cells to mitochondrial DNA damage or to oxidative damage.
An isolated polypeptide comprising SEQ ID NO:
- 2, wherein said isolated polypeptide effects a delay in cell cycle progression and increases sensitivity of cells to mitochondrial DNA damage or apoptosis induced by an oxidative stressor.
A method of treating a subject with a hyperproliferative disorder characterized by hyperproliferation of a particular cell type, said method comprising administering to the subject a therapeutically effective amount of SEQ ID NO:
- 2 or a functional fragment or derivative thereof, wherein said administering achieves delivery of SEQ ID NO:
- 2 or a functional fragment or derivative thereof to hyperproliferative cells in the subject, and said delivery effects a delay in cell cycle progression of the hyperproliferative cells and increases sensitivity of the hyperproliferative cells to mitochondrial DNA damage or apoptosis induced by an oxidative stressor and thereby reduces the number of hyperproliferative cells.
(canceled)
(canceled)
Dependencies are inferred from the claim text.